At a glance
ClinicalIndex Comparison RecordPhase 1Recruiting· 50 target
Drug / intervention
CpG-ODNcombination
Likely dose
Not stated in record
Key inclusion· 3
- ✓Advanced solid malignant tumors
- ✓Age 18-80 years
- ✓Life expectancy greater than 3 months
Key exclusion· 4
- ✕Benign tumors
- ✕Serious medical comorbidity
- ✕Life expectancy less than 3 months
- ✕Other unspecified exclusions
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Released by Interventional Approaches for Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University·interventional·Posted Jul 7, 2021·Updated Jun 26, 2024
In Brief
A Phase 1 clinical trial evaluating CpG-ODN for Lung Cancer and 2 related conditions. Currently recruiting, targeting 50 participants across 1 site.
Detailed Summary
To study the safety and clinical effects of intratumor injecting CpG-ODN and in situ release of tumor antigen by interventional ablation or drug-eluting beads to treat advanced solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer, Hepatocellular Carcinoma, Solid Tumor
CountriesChina
CollaboratorsGuangdong Zhaotai InVivo Biomedicine Co. Ltd.
Timeline
Phase 1Recruiting
2021202220232024202520262027202820292030203120322033203420352036
Enrollment StartMar 2021
First PostedJul 2021
TodayJul 2026
Primary CompletionJun 2029
Study CompletionJun 2036
First PostedJul 7, 2021
Enrollment StartMar 1, 2021
Primary CompletionJun 30, 2029
Study CompletionJun 30, 2036
TodayJul 1, 2026
Enrollment to primary: 8.3 yearsPosted 5.0 years agoPrimary completion in 3.0 years
Interventions
CpG-ODNcombination
CAR-T cells secreting scFv against OX40